Navigation Links
First and Only Single Capsule Daily Rx Prenatal Vitamin With Plant-Based DHA Now Available
Date:12/3/2008

predominantly found in fish and marine animal oils. Since many women do not consume the amount of DHA recommended by many experts in diet alone, a prescription prenatal vitamin with DHA can be just what a mother and her baby need to help ensure her DHA intake is greater than or equal to 200-300 mg per day during pregnancy and while breastfeeding.(10,12,13)

Developing infants cannot efficiently produce their own DHA, they must obtain this vital nutrient through the placenta during pregnancy or from an outside source such as breast milk after birth.(14) Mothers continuously lose their omega-3 fatty acid stores during pregnancy.(15) Furthermore, it takes an average of six months to recover from the loss, so a daily source of DHA is recommended by many health experts.(10,12)

PreNexa(TM) is a once daily single gel capsule that includes: Folic Acid (1.2 mg), Vitamin C (25 mg), Vitamin D3 (170 IU), Vitamin E (30 IU), Iron (30 mg), Calcium (160 mg) and Vitamin B6 (25 mg).(1) It also contains a gentle stool softener known as docusate sodium, which is an added benefit for approximately 50 percent of pregnant women who suffer from irregularity at some point in their pregnancy.(1,11)

PreNexa(TM) is available nationwide, by prescription only, in bottles containing a 30 day supply. This once-daily, single gel capsule with the most plant-based DHA, can be conveniently taken at anytime, day or night.

Upsher-Smith is pursuing drug therapies to improve people's lives. The company is driven by the ever-changing needs of patients, physicians, pharmacists and healthcare organizations. Focused on market expansion in women's health, dermatology, cardiology and in developing products for neurology, their perspective is not "more products" but the "right products" to improve lives. For additional information about PreNexa(TM), visit http://www.prenexa.com
'/>"/>

SOURCE Upsher-Smith Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. New approaches to protecting transplanted organs make first steps toward patients
2. Hill-Rom Announces First Quarter 2009 Dividend
3. First study to examine rare injuries and conditions of US high school athletes
4. Cantel Medical Corp. to Hold Conference Call to Discuss Results for Its First Quarter Ended October 31, 2008
5. USHIFU Announces First Sonablate(R) HIFU Device in India for Minimally Invasive Prostate Cancer Treatment
6. Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes
7. Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity
8. Asthma and Allergy Foundation Helps New First-Dad Keep His First Promise
9. In Support of World AIDS Day, FHSSA Announces New Partnerships That Include the First In-Country Partnerships in Namibia and The Gambia
10. Serotek First to Offer 64-Bit Support
11. Landauer, Inc. Increases Regular Cash Dividend and Declares First Quarter Payment
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine Technology:Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 2Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 3Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 4Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 5Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 6Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 7Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 8Efficacy and Safety Profile of Basilea's Alitretinoin for Severe,Refractory Chronic Hand Eczema Confirmed by Data Shown at European,Dermatology Congress 2Efficacy and Safety Profile of Basilea's Alitretinoin for Severe,Refractory Chronic Hand Eczema Confirmed by Data Shown at European,Dermatology Congress 3Efficacy and Safety Profile of Basilea's Alitretinoin for Severe,Refractory Chronic Hand Eczema Confirmed by Data Shown at European,Dermatology Congress 4Efficacy and Safety Profile of Basilea's Alitretinoin for Severe,Refractory Chronic Hand Eczema Confirmed by Data Shown at European,Dermatology Congress 5